Prime Therapeutics Appoints Scott Fries as Senior Vice President of Government Programs

Prime Therapeutics Appoints Scott Fries as Senior Vice President of Government Programs

ST. PAUL, Minn., June 3, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager, announced today that it has named Scott Fries as senior vice president of government programs. Fries will be responsible for leading the strategic direction and operations for Prime's Medicare, Medicaid and other government business.

"As the health care system continues to evolve, Scott's extraordinary track record in overseeing government programs will be an invaluable asset as Prime expands its membership in these markets," said Eric Elliott, president and CEO at Prime Therapeutics.

Fries comes to Prime from Optum, a UnitedHealth Care Company. Most recently, he served as senior vice president of solution and industry development where he was responsible for leading the development of integrated analytic, professional services and technology offerings for government programs. Prior to that, Fries held various leadership roles at Evercare, Ecolab and The Pillsbury Company.

Fries is a frequent speaker on industry related topics. He earned his Bachelor of Business Administration from the University of Wisconsin Eau Claire and his Masters of Business Administration from the University of Minnesota.

About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves nearly 20 million people. It is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.

For more information, visit or follow @Prime_PBM on Twitter.

SOURCE Prime Therapeutics

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.